BioNTech Pays $205 Million for Regulatory Speed as Court Hands Down Mixed Patent Ruling

BioNTech has agreed to pay $205 million in cash for a Priority Review Voucher from Scholar Rock, a move aimed at accelerating a future filing for one of its late-stage oncology candidates. The deal, announced Tuesday, remains subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino process. It is not yet complete.

The voucher is distinct from the FDA's Commissioner's National Priority Voucher program, which Reuters reported Monday—citing people familiar with the matter—has been paused. BioNTech's purchase concerns the Priority Review Voucher, a separate instrument, and would support a future marketing application rather than any approval already granted for a cancer medicine.

Patent Setback in The Hague

On the legal front, the Hague division of the Unified Patent Court ruled Tuesday that BioNTech and Pfizer's Comirnaty vaccine infringed a GSK patent covering RNA delivery. The court ordered the two companies to pay provisional damages of EUR 2 million. Enforcement of the injunction accompanying the ruling has been deferred pending a final decision, with a three-month window factored in for the parties to reach a licensing agreement. The injunction therefore stands but is not immediately enforceable.

Should investors sell immediately? Or is it worth buying BioNTech?

BioNTech shares slipped 2.7% on Monday. The report on the patent ruling does not establish a causal link between that decline and the court's decision.

Third-Quarter Earnings and a Raised Outlook

The flurry of news follows BioNTech's third-quarter 2026 results, published on November 3. Revenue came in at EUR 1.29 billion, with an IFRS net profit of EUR 184.5 million. Adjusted net profit, however, was lower than in the corresponding quarter a year earlier. For the first nine months of 2026, the company reported an IFRS net loss of EUR 1.17 billion.

Alongside the quarterly release last week, BioNTech raised the lower bound of its full-year 2026 revenue guidance. It now expects between EUR 1.7 billion and EUR 1.9 billion, citing third-quarter revenue development as the reason for the adjustment. That range is the upgraded annual forecast, while the quarterly figures describe results already booked.

Talks in Mainz Improve

At the company's Mainz headquarters, meanwhile, the atmosphere between management and the works council has improved, according to media reports on Tuesday. The reports, citing an internal works council communication, described difficult negotiations over job cuts. They concern the tone of the exchanges between the two sides; no conclusion to the talks was reported.

Ad

BioNTech Stock: New Analysis - 13 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...